# Ceritinib Rare Indications Study in ALK+ Tumors

> **NCT02465528** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Tumors With Aberrations in ALK
- Anaplastic Large Cell Lymphoma
- Inflammatory Myofibroblastic Tumor
- Glioblastoma

## Interventions

- **DRUG:** Ceritinib (LDK378)

## Key facts

- **NCT ID:** NCT02465528
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-06
- **Primary completion:** 2018-08-20
- **Final completion:** 2018-08-20
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02465528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02465528, "Ceritinib Rare Indications Study in ALK+ Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02465528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*